Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 30, 2025 08:30 ET | Source: Coherus Oncology, Inc.

Coherus Oncology to Report Third Quarter 2025 Financial Results on November 6, 2025

REDWOOD CITY, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Nasdaq: CHRS), today announced that its third quarter 2025 financial results will be released after market close on...
September 03, 2025 08:30 ET | Source: Coherus Oncology, Inc.

Coherus Oncology to Participate in Upcoming Investor Conferences

REDWOOD CITY, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ: CHRS) today announced that the company will be webcasting its participation in the following upcoming...
August 07, 2025 16:41 ET | Source: Coherus Oncology, Inc.

Coherus Oncology Reports Second Quarter 2025 Financial Results and Provides Business Update

– LOQTORZI net revenue was $10.0 million, a 36% increase over Q1 2025 – – Data readouts for CHS-114 and casdozokitug on track for 1H 2026 – – Q2 2025 ending cash, cash equivalents and...
July 31, 2025 16:45 ET | Source: Coherus Oncology, Inc.

Coherus Oncology to Report Second Quarter 2025 Financial Results on August 7, 2025

REDWOOD CITY, Calif., July 31, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Coherus, Coherus Oncology or the Company, Nasdaq: CHRS), today announced that its second quarter 2025 financial...
May 12, 2025 16:15 ET | Source: Coherus BioSciences, Inc.

Coherus BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update

– Strategic transformation to innovative oncology completed in Q2 2025 – – Positive CHS-114 (anti-CCR8 antibody) Phase 1b dose expansion study data in patients with head and neck cancer presented at...
May 01, 2025 17:04 ET | Source: Coherus BioSciences, Inc.

Coherus to Participate in Upcoming Investor Conferences

REDWOOD CITY, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that the company will be webcasting its participation in the upcoming...
April 14, 2025 08:00 ET | Source: Coherus BioSciences, Inc.

Coherus Completes Strategic Transformation with Successful Divestiture of UDENYCA® Franchise

– $250 million post-close cash balance extends cash runway over two years into 2027, funding pipeline development through key data catalysts – – Coherus to focus exclusively on its innovative novel...
March 10, 2025 16:12 ET | Source: Coherus BioSciences, Inc.

Coherus BioSciences Reports Fourth Quarter, Full Year 2024 Financial Results and Provides Business Update

– Annual net revenue increased 4% to $267.0 million in 2024, despite significant divestitures –– UDENYCA® net revenue increased 62% year-over-year –– LOQTORZI® net revenue increased 29%...
March 03, 2025 08:30 ET | Source: Coherus BioSciences, Inc.

Coherus to Report Fourth Quarter and Full Year 2024 Financial Results on March 10, 2025

REDWOOD CITY, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that its fourth quarter and full year 2024 financial results will be...
January 08, 2025 08:00 ET | Source: Coherus BioSciences, Inc.

Coherus Management to Present at the 43rd Annual J.P. Morgan Healthcare Conference

REDWOOD CITY, Calif., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that senior management will present at the 43rd Annual J.P. Morgan...